Christian Urban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christian Urban has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Herwig Lackner
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
7 shared publications - Martin Benesch
Division of Paediatric Haematology/Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria
6 shared publications - Wolfgang Schwinger
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
5 shared publications Herwig Lackner
Division of Paediatric Haematology/Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz
3 shared publications- Petra Sovinz
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria
3 shared publications - Volker Strenger
Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria
3 shared publications
Latest Publications
- 4 April 2017
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 229 (03) , 180-181
Central Hyperventilation in a Patient with Recurrent Acute Lymphoblastic Leukemia
Central hyperventilation (CH) is a respiratory pattern commonly observed in moribund patients due to advanced dysfunction of the respiratory centers in the brain stem. Hyperventilation which is not secondary to cardiorespiratory, metabolic or toxic disorders should lead the clinical suspicion to CH, which is defined as progressive tachypnea while awake and during sleep, accompanied by hypocapnia and respiratory alkalosis (Ledet et al., Neurology 2014; 82 (12): 1099–1100, Lange et al., J Neurol Neurosurg Psychiatry 1965; 28 (4): 317–319, Shahar et al., Pediatr Neurol 2004; 30 (4): 287–290). It is suspected to occur due to disruption of cortical inhibitory effects on the medullary respiratory centers, caused by various lesions of the cortex, the midbrain and the brainstem (Plum at al., AMA Arch Neurol Psychiatry 1959; 81 (5): 535–549, Gaviani et al., Neurology 2005; 64 (1): 166–167). CH has rarely been observed in conscious patients and in those cases it appeared mostly in the context of malignancies, involving the central nervous system (CNS). In adults CH seems to occur more frequently in association with cerebral lymphomas (Pauzner et al., Arch Neurol 1989; 46 (5): 510–512, Shibata et al., J Neurosurg 1992; 76 (4): 696–700). In children, data for this rare neurologic manifestation have not been reported in patients with hematologic malignancies. We describe a case of a child with an isolated CNS relapse of acute lymphoblastic leukemia (ALL) whose single presentation was CH.
- 4 April 2017
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 229 (03) , 180-181
Central Hyperventilation in a Patient with Recurrent Acute Lymphoblastic Leukemia
Central hyperventilation (CH) is a respiratory pattern commonly observed in moribund patients due to advanced dysfunction of the respiratory centers in the brain stem. Hyperventilation which is not secondary to cardiorespiratory, metabolic or toxic disorders should lead the clinical suspicion to CH, which is defined as progressive tachypnea while awake and during sleep, accompanied by hypocapnia and respiratory alkalosis (Ledet et al., Neurology 2014; 82 (12): 1099–1100, Lange et al., J Neurol Neurosurg Psychiatry 1965; 28 (4): 317–319, Shahar et al., Pediatr Neurol 2004; 30 (4): 287–290). It is suspected to occur due to disruption of cortical inhibitory effects on the medullary respiratory centers, caused by various lesions of the cortex, the midbrain and the brainstem (Plum at al., AMA Arch Neurol Psychiatry 1959; 81 (5): 535–549, Gaviani et al., Neurology 2005; 64 (1): 166–167). CH has rarely been observed in conscious patients and in those cases it appeared mostly in the context of malignancies, involving the central nervous system (CNS). In adults CH seems to occur more frequently in association with cerebral lymphomas (Pauzner et al., Arch Neurol 1989; 46 (5): 510–512, Shibata et al., J Neurosurg 1992; 76 (4): 696–700). In children, data for this rare neurologic manifestation have not been reported in patients with hematologic malignancies. We describe a case of a child with an isolated CNS relapse of acute lymphoblastic leukemia (ALL) whose single presentation was CH.
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 19 May 2008
- Published by Wiley in British Journal of Haematology
- Vol. 142 (4) , 504
Intramedullary aggregation and phagocytosis of neutrophils in chronic benign neutropenia of childhood
- 19 May 2008
- Published by Wiley in British Journal of Haematology
- Vol. 142 (4) , 504
Intramedullary aggregation and phagocytosis of neutrophils in chronic benign neutropenia of childhood
- 28 March 2008
- Published by Taylor & Francis in Pediatric Health
- Vol. 2 (2) , 147-149
Bevacizumab for Refractory Solid Tumors in Pediatric Patients
Evaluation of: Bender JL, Adamson PC, Reid JM et al.: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. J. Clin. Oncol. 26, 399–405 (2008). Angiogenesis is important for both tumor growth and development of metastases. Vascular endothelial growth factor is a potent proangiogenic factor. Bevacizumab, a humanized antibody against vascular endothelial growth factor is currently being tested for various malignancies among adult cancer patients, but has not yet been prospectively evaluated in children and young adults with malignant solid tumors. The results of the first Phase I trial of bevacizumab in this population are here presented by Bender et al. Bevacizumab administered at 5, 10 and 15 mg/kg doses every 2 weeks was well tolerated with no major toxicities (i.e., hemorrhage or thrombosis) observed. None of the patients achieved an objective response. Trials assessing combinations of bevacizumab with cytotoxic chem...
- 28 March 2008
- Published by Taylor & Francis in Pediatric Health
- Vol. 2 (2) , 147-149
Bevacizumab for Refractory Solid Tumors in Pediatric Patients
Evaluation of: Bender JL, Adamson PC, Reid JM et al.: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. J. Clin. Oncol. 26, 399–405 (2008). Angiogenesis is important for both tumor growth and development of metastases. Vascular endothelial growth factor is a potent proangiogenic factor. Bevacizumab, a humanized antibody against vascular endothelial growth factor is currently being tested for various malignancies among adult cancer patients, but has not yet been prospectively evaluated in children and young adults with malignant solid tumors. The results of the first Phase I trial of bevacizumab in this population are here presented by Bender et al. Bevacizumab administered at 5, 10 and 15 mg/kg doses every 2 weeks was well tolerated with no major toxicities (i.e., hemorrhage or thrombosis) observed. None of the patients achieved an objective response. Trials assessing combinations of bevacizumab with cytotoxic chem...
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 31 March 2007
- Published by Wiley in Pediatric Transplantation
- Vol. 11 (3) , 332-335
Durable remission following a third allogeneic stem cell transplantation in a patient with repeatedly relapsing SAA. The importance of stroma cells for sustained engraftment?
Diagnosis of acquired AATP which finally progressed to SAA was established in an eight-yr-old boy. PBSCT from an HLA-identical unrelated donor using high numbers of CD34+ selected stem cells was performed and resulted in complete remission for almost two yr. However, SAA reoccurred with 100% donor hematopoiesis and was reversed by a second CD 34+ selected PBSCT from the same donor. Declining blood cell counts after an interval of two yr indicated second relapse. Chimerism analysis in PB and BM aspirates revealed a small autologous cell population of 4-12% and 2-11%, respectively. Finally, a third transplantation with unmanipulated BM from the same donor resulted in sustained remission with 100% donor hematopoiesis. The patient is in complete remission for more than five yr following the third SCT. Late graft failure or late graft rejection known to occur after transplantation of highly purified CD34+ cells, or even graft exhaustion caused by stromal dysfunction due to the underlying disease necessitated a third transplantation. Regardless of the cause of relapse, transplantation of unmanipulated BM instead of highly purified PBSCTs led to a permanent and stable engraftment in a third attempt after two previous PBSCTs.
- 31 March 2007
- Published by Wiley in Pediatric Transplantation
- Vol. 11 (3) , 332-335
Durable remission following a third allogeneic stem cell transplantation in a patient with repeatedly relapsing SAA. The importance of stroma cells for sustained engraftment?
Diagnosis of acquired AATP which finally progressed to SAA was established in an eight-yr-old boy. PBSCT from an HLA-identical unrelated donor using high numbers of CD34+ selected stem cells was performed and resulted in complete remission for almost two yr. However, SAA reoccurred with 100% donor hematopoiesis and was reversed by a second CD 34+ selected PBSCT from the same donor. Declining blood cell counts after an interval of two yr indicated second relapse. Chimerism analysis in PB and BM aspirates revealed a small autologous cell population of 4-12% and 2-11%, respectively. Finally, a third transplantation with unmanipulated BM from the same donor resulted in sustained remission with 100% donor hematopoiesis. The patient is in complete remission for more than five yr following the third SCT. Late graft failure or late graft rejection known to occur after transplantation of highly purified CD34+ cells, or even graft exhaustion caused by stromal dysfunction due to the underlying disease necessitated a third transplantation. Regardless of the cause of relapse, transplantation of unmanipulated BM instead of highly purified PBSCTs led to a permanent and stable engraftment in a third attempt after two previous PBSCTs.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (3) , 209-219
CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS IN FOUR CHILDREN WITH GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH
The incidence of gastrointestinal stromal tumors (GISTs) in children is exceptionally low. However, during the last decade these tumors attracted increasing attention, because they were found to express the cell surface transmembrane receptor kit (CD117) that has tyrosine kinase activity. This tyrosine kinase can be semi-selectively inhibited by signal transduction inhibitors such as imatinib mesylate (Glivec), which is a competitive inhibitor of c-kit, c-abl, platelet-derived growth factor receptor-α (PDGFR-α) and PDGFR-β, and abl-related gene (arg). The authors present the clinical, radiographic, and pathological findings of 4 children who were diagnosed with gastric GIST. One of them had an incomplete Carney triad including GIST and mediastinal paraganglioma. All 4 patients presented with anemia and anemia-related symptoms and underwent total resection of the tumor. One patient received additional chemotherapy (in the pre-imatinib era) and 2 patients received a short course of imatinib mesylate. With a follow-up of 116, 55, 23, and 10 months all patients are alive in first complete continuous remission. In children and adolescents, particularly in female patients, GISTs should be included in the differential diagnosis of anemia secondary to gastrointestinal hemorrhage. Complete surgical resection is the mainstay of treatment for this tumor, with imatinib mesylate restricted to patients with advanced or metastatic tumors. Since late recurrences (up to 30 years following initial diagnosis) are reported, a life-long follow-up is mandatory in these patients.
- 1 January 2007
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 24 (3) , 209-219
CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS IN FOUR CHILDREN WITH GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH
The incidence of gastrointestinal stromal tumors (GISTs) in children is exceptionally low. However, during the last decade these tumors attracted increasing attention, because they were found to express the cell surface transmembrane receptor kit (CD117) that has tyrosine kinase activity. This tyrosine kinase can be semi-selectively inhibited by signal transduction inhibitors such as imatinib mesylate (Glivec), which is a competitive inhibitor of c-kit, c-abl, platelet-derived growth factor receptor-α (PDGFR-α) and PDGFR-β, and abl-related gene (arg). The authors present the clinical, radiographic, and pathological findings of 4 children who were diagnosed with gastric GIST. One of them had an incomplete Carney triad including GIST and mediastinal paraganglioma. All 4 patients presented with anemia and anemia-related symptoms and underwent total resection of the tumor. One patient received additional chemotherapy (in the pre-imatinib era) and 2 patients received a short course of imatinib mesylate. With a follow-up of 116, 55, 23, and 10 months all patients are alive in first complete continuous remission. In children and adolescents, particularly in female patients, GISTs should be included in the differential diagnosis of anemia secondary to gastrointestinal hemorrhage. Complete surgical resection is the mainstay of treatment for this tumor, with imatinib mesylate restricted to patients with advanced or metastatic tumors. Since late recurrences (up to 30 years following initial diagnosis) are reported, a life-long follow-up is mandatory in these patients.
- 13 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 1012-1014
Clinical appearance of neuroblastoma 10 years after screening
A follow-up study was performed for children with previous repeated positive results by neuroblastoma mass screening and negative clinical results (30 out of 439,128 children screened in Austria between 1991 and 2003, median follow-up 113 months). Four children had continuously elevated urine catecholamines for more than 6 months. One of these patients was diagnosed with pelvic neuroblastoma and multiple metastases 10 years after the first positive screening result. In the light of a 'wait and see' strategy for localized neuroblastomas, our observation suggests that these patients should be further observed even after normalization of urine catecholamines.
- 13 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 1012-1014
Clinical appearance of neuroblastoma 10 years after screening
A follow-up study was performed for children with previous repeated positive results by neuroblastoma mass screening and negative clinical results (30 out of 439,128 children screened in Austria between 1991 and 2003, median follow-up 113 months). Four children had continuously elevated urine catecholamines for more than 6 months. One of these patients was diagnosed with pelvic neuroblastoma and multiple metastases 10 years after the first positive screening result. In the light of a 'wait and see' strategy for localized neuroblastomas, our observation suggests that these patients should be further observed even after normalization of urine catecholamines.